Nuvation Bio Exercises Full Greenshoe Option in $287.5 Million Notes Offering

Nuvation Bio Inc. (NYSE: NUVB) has announced that its underwriters have fully exercised their over-allotment option on the company's $287.5 million convertible senior notes offering. The greenshoe option allows the underwriters to purchase additional notes.

The offering, announced earlier this month, initially comprised $200 million in aggregate principal amount of notes plus an additional $87.5 million option. Proceeds from the notes are earmarked for funding research and development, including advancing the company's pipeline of cancer drug candidates. A broader industry goal is to secure long-term financing for early-stage drug development.

Nuvation Bio, an oncology company focused on cancer treatment, aims to develop novel therapeutics. The company's drug candidates are currently in early-stage development, with investors closely monitoring progress in preclinical and clinical studies. The company has its headquarters in New York.

With the exercise of the notes, Nuvation Bio has secured additional capital, strengthening its financial position to continue its oncology research and development efforts. The notes offering provides the company with financial flexibility.